Early Recognition Inventory for the Retrospective Assessment of the Onset of Schizophrenia Checklist--Italian Version

Meneghelli, Anna; Alpi, A.; Cascio, M. T.; Häfner, Heinz; Maurer, K.; Preti, A.; Raballo, Andrea; Cocchi, Angelo

doi:10.1037/t61626-000

Cited by 8 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the success of preventive approaches also depends on a sufficiently high rate of target persons who are reached by it. Thus, to reach also CHR persons who do not actively seek help for their mental problems, more research in the general population is needed to develop ethically justified means such as well-validated and reliable screeners [68] on the basis of those already proposed [49,66,85].…”

Section: Discussionmentioning

confidence: 99%

EPA guidance on the early detection of clinical high risk states of psychoses

et al. 2015

Self Cite

View full text Add to dashboard Cite

The aim of this guidance paper of the European Psychiatric Association is to provide evidence-based recommendations on the early detection of a clinical high risk (CHR) for psychosis in patients with mental problems. To this aim, we conducted a meta-analysis of studies reporting on conversion rates to psychosis in non-overlapping samples meeting any at least any one of the main CHR criteria: ultra-high risk (UHR) and/or basic symptoms criteria. Further, effects of potential moderators (different UHR criteria definitions, single UHR criteria and age) on conversion rates were examined. Conversion rates in the identified 42 samples with altogether more than 4000 CHR patients who had mainly been identified by UHR criteria and/or the basic symptom criterion 'cognitive disturbances' (COGDIS) showed considerable heterogeneity. While UHR criteria and COGDIS were related to similar conversion rates until 2-year follow-up, conversion rates of COGDIS were significantly higher thereafter. Differences in onset and frequency requirements of symptomatic UHR criteria or in their different consideration of functional decline, substance use and co-morbidity did not seem to impact on conversion rates. The 'genetic risk and functional decline' UHR criterion was rarely met and only showed an insignificant pooled sample effect. However, age significantly affected UHR conversion rates with lower rates in children and adolescents. Although more research into potential sources of heterogeneity in conversion rates is needed to facilitate improvement of CHR criteria, six evidence-based recommendations for an early detection of psychosis were developed as a basis for the EPA guidance on early intervention in CHR states.

show abstract

Section: Discussionmentioning

confidence: 99%

EPA guidance on the early detection of clinical high risk states of psychoses

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…The DUP was measured (in weeks) as the time elapsed from the onset of key symptoms (hallucinations, delusions, or bizarre behaviour) to the beginning of treatment (pharmacotherapy/psychotherapy) prescribed by a psychiatrist. This evaluation was made with the Italian version of the Early Recognition Inventory Retrospective Assessment of Symptoms checklist (ERIraos-CL) [ 40 ], a 17-item screening checklist intended to select persons needing a more in-depth assessment. The ERIraos-CL has 17 items designed to assist the exploration of individual proneness to schizophrenia, including items about changes in perception and thought interference and 2 items about paranoid ideation and hallucinations, which are more clearly indicative of psychosis [ 41 , 42 ].…”

Section: Methodsmentioning

confidence: 99%

Duration of Untreated Disorder and Cannabis Use: An Observational Study on a Cohort of Young Italian Patients Experiencing Psychotic Experiences and Dissociative Symptoms

Ricci

Martinotti

Ceci

et al. 2021

IJERPH

View full text Add to dashboard Cite

Background: The Duration of Untreated Psychosis (DUP) is the time between the first-episode psychosis (FEP) and the initiation of antipsychotic treatment. It is an important predictor of several disease-related outcomes in psychotic disorders. The aim of this manuscript is investigating the influence of cannabis on the DUP and its clinical correlates. Methods: During years 2014–2019, sixty-two FEP patients with and without cannabis use disorder (CUD) were recruited from several Italian psychiatric hospitals. The subjects were then divided into two groups based on the duration of the DUP and assessed at the beginning of the antipsychotic treatment and after 3 and 6 months, using the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF) scale, and the Dissociative Experiences Scale (DES-II). Results: As expected, a longer DUP was associated with worse symptoms and cannabis use did not seem to affect the DUP, but both were related with more dissociative symptoms at onset and over time. Discussion: According to our study, cannabis use can be a predictor of FEP and DUP, and of disease outcome. However, several factors might influence the relationship between cannabis use and DUP. Preventing cannabis use and early diagnosis of psychotic disorders might impact the disease by reducing the persistence of symptoms and limiting dissociative experiences.

show abstract

“…This second-level evaluation is carried out in specialized centers and aims to carefully detect imminent transition [115]. Thereafter, the ERIraos has been successfully employed as a tool for the early recognition of psychosis risk in several further German studies [116][117][118] and subsequently translated and validated into different languages and populations [115,119]. This instrument proved to be suitable for routine use as a scale for the identification of the at-risk subjects.…”

Section: Integrated Model Of Prevention and Early Detection Of The Onset In Primary Psychosismentioning

confidence: 99%

Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset

et al. 2021

View full text Add to dashboard Cite

Primary psychosis, which includes schizophrenia and other psychoses not caused by other psychic or physical conditions, has a strong impact worldwide in terms of disability, suffering and costs. Consequently, improvement of strategies to reduce the incidence and to improve the prognosis of this disorder is a current need. The purpose of this work is to review the current scientific literature on the main risk and protective factors of primary psychosis and to examine the main models of prevention, especially those related to the early detection of the onset. The conditions more strongly associated with primary psychosis are socio-demographic and economic factors such as male gender, birth in winter, ethnic minority, immigrant status, and difficult socio-economic conditions while the best-established preventive factors are elevated socio-economic status and an economic well-being. Risk and protective factors may be the targets for primordial, primary, and secondary preventive strategies. Acting on modifiable factors may reduce the incidence of the disorder or postpone its onset, while an early detection of the new cases enables a prompt treatment and a consequential better prognosis. According to this evidence, the study of the determinants of primary psychosis has a pivotal role in designing and promoting preventive policies aimed at reducing the burden of disability and suffering of the disorder.

show abstract

Early Recognition Inventory for the Retrospective Assessment of the Onset of Schizophrenia Checklist--Italian Version

Cited by 8 publications

References 0 publications

EPA guidance on the early detection of clinical high risk states of psychoses

EPA guidance on the early detection of clinical high risk states of psychoses

Duration of Untreated Disorder and Cannabis Use: An Observational Study on a Cohort of Young Italian Patients Experiencing Psychotic Experiences and Dissociative Symptoms

Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset

Contact Info

Product

Resources

About